The ongoing surge in licensing deals for early drug prospects should continue this year and involve more cell and gene ...
On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” ...
For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...
Amid a rebound in SPAC activity, the prolific “crossover” investor is aiming for its third blank-check merger since 2022 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results